The regulatory network involving the interactions between SDHAP1, miR-4465, and EIF4G2 could represent a promising therapeutic target for treating ovarian cancer that has developed resistance to paclitaxel chemotherapy.179. Here, SDHAP1 is linked to ovarian carcinoma.